Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Marco J. Schnabel"'
Autor:
Ingmar Wolff, Martin Burchardt, Julia Peter, Christian Thomas, Danijel Sikic, Christian Fiebig, Sören Promnitz, Bernd Hoschke, Maximilian Burger, Marco J. Schnabel, Christian Gilfrich, Niklas Löbig, Nina N. Harke, Florian A. Distler, Matthias May
Publikováno v:
Cancers, Vol 15, Iss 10, p 2830 (2023)
Certification as a prostate cancer center requires the offer of several supportive measures to patients undergoing radical prostatectomy (RP). However, it remains unclear how patients estimate the relevance of these measures and whether the availabil
Externí odkaz:
https://doaj.org/article/c0a302386be54b288379dff9e373f42b
Autor:
Ingmar Wolff, Martin Burchardt, Christian Gilfrich, Julia Peter, Martin Baunacke, Christian Thomas, Johannes Huber, Rolf Gillitzer, Danijel Sikic, Christian Fiebig, Julie Steinestel, Paola Schifano, Niklas Löbig, Christian Bolenz, Florian A. Distler, Clemens Huettenbrink, Maximilian Janssen, David Schilling, Bara Barakat, Nina N. Harke, Christian Fuhrmann, Andreas Manseck, Robert Wagenhoffer, Ekkehard Geist, Lisa Blair, Jesco Pfitzenmaier, Bettina Reinhardt, Bernd Hoschke, Maximilian Burger, Johannes Bründl, Marco J. Schnabel, Matthias May
Publikováno v:
Cancers, Vol 14, Iss 21, p 5356 (2022)
Patient’s regret (PatR) concerning the choice of therapy represents a crucial endpoint for treatment evaluation after radical prostatectomy (RP) for prostate cancer (PCA). This study aims to compare PatR following robot-assisted (RARP) and open sur
Externí odkaz:
https://doaj.org/article/3fff2cbea38f4c64a94fa782e4f72f25
Autor:
Felix Riedel, Mara Münker, Florian Roghmann, Johannes Breyer, Marco J. Schnabel, Maximilian Burger, Danijel Sikic, Thomas Büttner, Manuel Ritter, Kiriaki Hiller, Felix Wezel, Christian Bolenz, Friedemann Zengerling
Publikováno v:
Cancers, Vol 14, Iss 12, p 2850 (2022)
Background: Immune checkpoint inhibitors (ICI) are standard of care in patients with metastatic urothelial carcinoma (mUC) ineligible for cisplatin, and as second-line therapy after platinum-based chemotherapy. To date, few data exist about the effic
Externí odkaz:
https://doaj.org/article/cb2d676ca5b34db3a3600297f3df4220
Autor:
Sumanta K Pal, Diederik M Somford, Petros Grivas, Srikala S Sridhar, Shilpa Gupta, Joaquim Bellmunt, Guru Sonpavde, Mark T Fleming, Seth P Lerner, Yohann Loriot, Jean Hoffman-Censits, Begoña P Valderrama, Corina Andresen, Marco J Schnabel, Suzanne Cole, Siamak Daneshmand
Publikováno v:
Future Oncology. 18:2599-2614
PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract ur
Autor:
Mario W. Kramer, Julian P. Struck, Hubert Kuebler, Marie C. Hupe, Tomasz Ozimek, Boris Hadaschik, Marco J. Schnabel, Immanuel A Oppolzer, Maximilian Burger, Viktor Gruenwald, Maximilian Weinke, Christian Gratzke, Markus Grabbert, Alexander Katalinic, Maike Schnoor, Andrea Schulze, Jonas C Klockenbusch, Christopher Darr, Axel S. Merseburger
Publikováno v:
World Journal of Urology
PurposeTo date, over 4.2 million Germans and over 235 million people worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Uro-oncology (UO) patients are particularly vulnerable but in urgent need of life-sav
Publikováno v:
Der Urologe. 60:1167-1174
Cisplatin-based chemotherapy regimens represent the standard of care in patients with locally advanced or metastatic urothelial carcinoma of the bladder. However, many patients are ineligible for cisplatin due to comorbidities or performance status.
Autor:
Max Bürger, Marco J. Schnabel, Philipp J. Spachmann, H.-M. Fritsche, M Steckermeier, Bernd Rosenhammer
Publikováno v:
International Urology and Nephrology. 53:1551-1556
To assess the feasibility of sparing routine antibiotic prophylaxis in patients without preoperative urinary tract infection (UTI) undergoing a miniaturized percutaneous nephrolithotomy (mPCNL). A retrospective, monocentric study was conducted to eva
Autor:
Marco J. Schnabel, Paul Schmitz
Publikováno v:
Der Urologe. 60:1591-1593
Autor:
Sumanta K, Pal, Diederik M, Somford, Petros, Grivas, Srikala S, Sridhar, Shilpa, Gupta, Joaquim, Bellmunt, Guru, Sonpavde, Mark T, Fleming, Seth P, Lerner, Yohann, Loriot, Jean, Hoffman-Censits, Begoña P, Valderrama, Corina, Andresen, Marco J, Schnabel, Suzanne, Cole, Siamak, Daneshmand
Publikováno v:
Future oncology (London, England). 18(21)
PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract ur
Publikováno v:
Uro-News